Tris-Hydroxymethyl Aminomethane in Critically Ill Adults: A Systematic Review
Authors' conclusion
We conclude that THAM may have potential advantages in some critical care settings, but that clinical evidence is limited
Study context
- Population
- Critically ill adults receiving tris-hydroxymethyl aminomethane (THAM) in the operative or critical care setting (surgical and nonsurgical patients, liver transplantation, acute respiratory distress syndrome (ARDS))
- Participants
- 417 adults · 21 studies
- Comparison
- THAM as a buffering agent
- THAMn = 417
- Outcome
- Efficacy and safety of THAM as a buffering agent
Pooled result
As reported in the abstract
Correction of acidosis
- THAM corrected acidosis with efficacy equivalent to sodium bicarbonate, with less hypercarbia and hypernatremia
- 3 RCTs, 5 observational studies, 4 case series, 9 case reports; 8 (38%) conference abstracts
Safety
Adverse effects of THAM
- Hyperkalemia, hypoglycemia, ventilator depression, tissue damage with extravasation
Original publication
Tris-Hydroxymethyl Aminomethane in Critically Ill Adults: A Systematic Review. Anesth Analg. Published 19 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →